ClinicalTrials.gg
CompletedNCT03245229Updated Nov 29, 2022

A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)

A Phase 1 interventional study of Aprocitentan and Rosuvastatin in Healthy Subjects, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Czechia. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-29.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The primary purpose of this study is to investigate the effect of Aprocitentan (ACT-132577) at steady state on the pharmacokinetics of single-dose rosuvastatin in healthy male subjects

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in the local language prior to any study mandated procedure;
  • Healthy male subjects aged 18 to 45 years (inclusive) at screening;
  • of 18.0 to 28.0 kg/m2 (inclusive) at screening;
  • Healthy on the basis of physical examination, cardiovascular assessments and laboratory tests;
  • ≥ 135 g/L at screening.

Exclusion criteria

Exclusion Criteria:

  • Known allergic reactions or to ACT-132577, rosuvastatin, any drug of the same classes, or any of their ;
  • Any for rosuvastatin treatment;
  • History or clinical evidence of myopathy;
  • Asian or Indian-Asian ethnicity;
  • Known hypersensitivity or allergy to natural rubber latex;
  • Previous exposure to ACT-132577;
  • Treatment with rosuvastatin within 3 months prior to screening;
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Treatment A

    In the morning of Day 1, a single dose of 10 mg rosuvastatin will be administered in the fasted state followed by an observation period of 96 h

    Drug: Rosuvastatin

  • Experimental
    Treatment B1

    25 mg ACT-132577 will be administered o.d. from Day 5 to Day 12

    Drug: Aprocitentan

  • Experimental
    Treatment B2

    In the morning of Day 13, a single dose of 10 mg rosuvastatin will be administered in the fasted state, concomitantly with 25 mg ACT-132577, followed by an observation period of 120 h. Doses of 25 mg ACT-132577 will be administered o.d. from Day 14 to Day 17.

    Drug: Aprocitentan · Drug: Rosuvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax) of rosuvastatin

    Cmax of rosuvastatin will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: Up to Day 29

  2. Time to reach Cmax (tmax) of rosuvastatin

    tmax of rosuvastatin will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: Up to Day 29

  3. Terminal half-life (t1/2) of rosuvastatin

    t1/2 of rosuvastatin will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: Up to Day 29

  4. Area under the plasma concentration-time curves during a dosing interval [AUC(0-t)] of rosuvastatin

    AUC(0-t) of rosuvastatin will be derived by non-compartmental analysis of the plasma concentration-time profiles

    Time frame: Up to Day 29

  5. Area under the plasma concentration-time curves from time 0 to inf [AUC(0-inf)] of rosuvastatin

    AUC(0-inf) of rosuvastatin will be derived by non-compartmental analysis of the plasma concentration-time profile

    Time frame: Up to Day 29

  6. Trough (pre-dose) plasma concentrations (Ctrough) of ACT-132577

    Ctrough of ACT-132577 will be derived by non-compartmental analysis of the plasma concentration-time profile

    Time frame: Up to Day 29

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Treatment emergent adverse events and treatment emergent serious adverse events will be evaluated throughout the study

    Time frame: Up to Day 29

  2. Changes from baseline in electrocardiogram (ECG) variables

    ECG variables are to be recorded at rest using a standard 12-lead ECG

    Time frame: Up to Day 29

  3. Changes from baseline in blood pressure

    Blood pressure (mmHg) measured using an automatic oscillometric device

    Time frame: Up to Day 29

  4. Changes from baseline in pulse rate

    Pulse rate (bpm) measured using an automatic oscillometric device

    Time frame: Up to Day 29

07

Study locations

1 site
  • Cepha s.r.o
    Plzen, 32300, Czechia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Sep 2017, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2017
First posted
Aug 10, 2017
StartActual
Aug 10, 2017
Primary completionActual
Sep 18, 2017
CompletionActual
Sep 18, 2017
Last update
Nov 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03245229
Responsible party
Sponsor
First posted
Aug 10, 2017
Start date
Aug 10, 2017
Primary completion
Sep 18, 2017
Completion
Sep 18, 2017
Last update
Nov 29, 2022

Study contacts

Clinical Trial
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aprocitentan · Rosuvastatin

Start the discussion